Biocon Planning to List Biosimilars Business on Stock Exchanges by March 2026

Biocon, the leading Indian biopharmaceutical company, has announced plans to list its biosimilars business on the stock exchanges by March 2026. The company is also targeting a significant expansion of its market share in the United States, aiming for a double-digit share for its upcoming biosimilar launches in the region.

Biosimilars are affordable alternatives to biologic drugs, which are often expensive and used to treat complex conditions such as cancer, diabetes, and autoimmune diseases. Biocon Biologics CEO, Shreehas Tambe, shared these details in a recent interview with Reuters. According to Tambe, the company aims to launch five new biosimilars in the U.S. starting in the new fiscal year, beginning in April. The company is hopeful that these launches will help them capture a notable portion of the U.S. market.

Tambe explained that Biocon wanted to ensure full control over its biosimilars business before moving forward with its IPO plans. "We needed to be in charge and control of the business before taking the company public," he said. The company is now in the final stages of integrating Viatris, a biosimilars firm it acquired, and is also working on refinancing its debt. With these steps nearing completion, Biocon plans to move forward with listing its biosimilars business within the next 12 to 15 months, targeting a March 2026 listing date.

Biocon has made significant strides in the biosimilars space. The company’s existing biosimilars currently hold a 20% market share in their respective segments. In addition to the five new biosimilars planned for the U.S., Biocon is also focusing on expanding its reach in Europe, where it plans to introduce three more biosimilars in the next 18 months.
The U.S. remains the largest contributor to Biocon’s revenue, accounting for around 40% of the company's earnings. Europe follows closely, with 35% of revenue coming from the region. The company has also expressed confidence in the potential impact of U.S. healthcare reforms under President Joe Biden's administration. Tambe sees a bipartisan push towards affordable healthcare, with biosimilars playing a crucial role in achieving this goal.

Looking ahead, Biocon hopes that these strategies, alongside the public listing of its biosimilars business, will help the company continue its growth and strengthen its position as a leader in the global biopharmaceutical market.

In Conclusion

Biocon’s plans to list its biosimilars division and expand its product portfolio in the U.S. and Europe represent a significant step in its growth strategy. With a focus on market expansion, product innovation, and affordable healthcare, Biocon aims to continue delivering value for shareholders and patients alike.